Solifenacin in the treatment of urgency and other symptoms of overactive bladder: Results from a randomized, double-blind, placebo-controlled, rising-dose trial

BJU International

Volumn 102, Issue 9, 2008, Pages 1120-1127

  Cardozo, Linda ^a,i   Heßdörfer, Elke ^b   Milani, Rodolfo ^c   Arañó, Pedro ^d   Dewilde, Luc ^e   Slack, Mark ^f   Drogendijk, Ted ^g   Wright, Mark ^h   Bolodeoku, John ^h   De Ridder, D ^b   Opsomer, R ^b   Quackels, T ^b   Vekemans, K ^b   Vossaert, P ^b   Ampe, J ^b   De Leval, J ^b   Van Erps, P ^b   Dhont, M ^b   Pavlik, I ^b   Feyereisl, J ^b   Mokris, J ^b   Adamik, Z ^b   Krut, J ^b   Wadie, B ^b   Haab, F ^b   Deval, B ^b   Amarenco, G ^b   Costa, P ^b   Labat, J J ^b   Ansieau, J P ^b   Biserte, J ^b   Mauroy, B ^b   Benusch, T ^b   Hechelmann, W ^b   Hentschel, M ^b   Kaesler, F P ^b   Klammert, P ^b   Laval, K U ^b   Mertins, D ^b   Muhlich S ^b   Ostwald, R ^b   Sawaya, P ^b   Schmidt, P ^b   Spelmeyer, D ^b   Vilmar, W ^b   Willgerodt, J ^b   Sofikitis, N ^b   Sofras, F ^b   Theodorou, C ^b   Farkas, L ^b   Kiss, L ^b   Nagy, G ^b   Pajor, L ^b   Toth Z ^b   Adile, B ^b   Carone, R ^b   Damiano, R ^b   Di Benedetto, P ^b   Ferrari, P ^b   Meschia, M ^b   Selvaggi, L ^b   Lorenz, J ^b   Wolski, Z ^b   Costa, L ^b   Guimaraes M ^b   Matos Ferreira, A ^b   Vasco, P ^b   Abashin, V ^b   Al Shukri, S H ^b   Apolikhina, I ^b   Avdoshin, V ^b   Gomberg, V ^b   Loran, O B ^b   Mazo, E B ^b   Petrov, S ^b   Pushkar, D ^b   Trapeznikova, M F ^b   Zakhmatov, Y M ^b   Balaz V ^b   Kliment, J ^b   Mikulas, J ^b   Castro Diaz, D ^b   Duenas, E ^b   Garcia Sastre, E ^b   Leva, M ^b   Llorente Abarca, C ^b   Parra, J L ^b   Romero, J A ^b   Sanchez Chapado M ^b   Almallah, Z ^b   Barrington, J ^b   Beard, R ^b   Britton, J P ^b   Greene, D ^b   Hetherington, J ^b   Leather, A ^b   Lui, S ^b   Monga, A ^b   Pearce, I ^b   Stewart, L ^b   Thakar, R ^b   Vanwaeyenbergh, J ^b   Wagg, A ^b   Webb, R ^b   Leunissen, P ^b   Macfarlane, D ^b   Mollee, H ^b   Vink, E ^b   more..

^a KING'S COLLEGE LONDON   (United Kingdom)

^b Milano Bicocca University ^*

^c SAN GERARDO HOSPITAL   (Italy)

^d FUNDACIÓ PUIGVERT   (Spain)

^e ZiekenhuisNetwerk Antwerpen   (Belgium)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^g Astellas Pharma Global Development   (Netherlands)

^h ASTELLAS PHARMA EUROPE LTD   (United Kingdom)

ⁱ KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Incontinence; Overactive bladder; PPIUS; Solifenacin; Urgency

Indexed keywords

PLACEBO; SOLIFENACIN;

ADULT; AGED; ARTICLE; BLURRED VISION; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; OVERACTIVE BLADDER; PATIENT SATISFACTION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; URINARY FREQUENCY; URINARY URGENCY; URINE INCONTINENCE; XEROSTOMIA;

EID: 53849118462     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.07939.x     Document Type: Article

References (14)

1. Irwin DE, Milsom I, Hunskaar S et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006 50 : 1306 15
2. Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001 87 : 760 6
3. Stewart WF, Van Rooyen JB, Cundiff GW et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003 20 : 327 36
4. Abrams P, Cardozo L, Fall M et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002 21 : 167 78
5. Abrams P, Artibani W, Cardozo L, Dmochowski R, van Kerrebroeck P, Sand P. Reviewing the ICS 2002 terminology report: the ongoing debate. Neurourol Urodyn 2006 25 : 293 4
6. Chapple CR, Artibani W, Cardozo LD et al. The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects. BJU Int 2005 95 : 335 40
7. Payne CK, Kelleher C. Redefining response in overactive bladder syndrome. BJU Int 2007 99 : 101 6
8. Chapple CR, Cardozo L, Steers WD, Govier FE. Solifenacin significantly improves all symptoms of overactive bladder syndrome. Int J Clin Pract 2006 60 : 959 66
9. Chapple CR, Martinez-Garcia R, Selvaggi L et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005 48 : 464 70
10. Michel MC, de la Rosette JJMCH. Role of muscarinic receptor antagonists in urgency and nocturia. BJU Int 2005 96 (Suppl. 1 37 42
11. Committee for Proprietary Medicinal Products. Note for Guidance on the Clinical Investigation of Medicinal Products for the Treatment of Urinary Incontinence. CPMP/EWP/18/01. London : EMEA (European Agency for the Evaluation of Medicinal Products), 2002
12. Michel M, Wetterauer U, Vogel M, de la Rosette JJ. Cardiovascular safety of solifenacin in routine clinical use. Urology 2008 68 : 71 2
13. Artibani W. Outcomes in overactive bladder treatment: patient perception - a key to success. Eur Urol Suppl 2007 6 : 17 22
14. Schagen van Leeuwen JH, Castro R, Busse M, Bemelmans BLH. The placebo effect in the pharmacologic treatment of patients with lower urinary tract symptoms. Eur Urol 2006 50 : 440 53